Neurocrine biosciences presents data on treatment of patients with congenital adrenal hyperplasia at ece 2023
Post hoc analyses of phase 2 study of crinecerfont in adults with cah demonstrate androgen reduction across a broad range of glucocorticoid doses post hoc analyses of phase 3 study demonstrate efmody® (hydrocortisone modified-release hard capsules) reduced androgen levels compared to immediate-release hydrocortisone in patients with cah san diego , may 12, 2023 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix), a leading neuroscience-focused biopharmaceutical company, today announced that it will present new analyses of phase 2 data of the investigational drug crinecerfont in adults with classic congenital adrenal hyperplasia (cah) due to 21-hydroxylase deficiency (21-ohd) and post hoc analyses of phase 3 data for efmody® (hydrocortisone modified-release hard capsules). efmody is approved by the european commission for the european economic area (including northern ireland) (eea) and by the uk medicines and healthcare products regulatory agency (mhra) for the treatment of adults and adolescents (12 years and older) with cah.
NBIX Ratings Summary
NBIX Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission